EACS2023: 416 Comparative efficacy and safety of TAF/FTC/BIC, TAF/FTC+DTG, and TDF/FTC+DTG in naive people with HIV: results from the SCOLTA cohort A. De Vito , E. Ricci , N. Squillace , G. Calleri , G.F. Pellicanò , E. Sarchi , A. Bandera , B. Menzaghi , S. Piconi , G.V. De Socio , A. Colpani , M.B. Celesia , S. Ferrara , P. Maggi , M.A. Carleo , A. Cascio , G. Orofino , A. Di Biagio , P. Bonfanti , G. Madeddu , CISAI Study Group University of Sassari, Unit of Infectious Diseases, Department of Medicine, Surgery, and Pharmacy, Sassari, Italy, Fondazione ASIA Onlus, Milan, Italy, Fondazione IRCCS San Gerardo dei Tintori - University of Milano-Bicocca, Infectious Diseases Clinic, Milan, Italy, Amedeo di Savoia Hospital, Unit of Infectious Diseases, “Divisione A”, Sassari, Italy, University of Messina, Unit of Infectious Diseases, Department of Human Pathology of the Adult and the Developmental Age “G. Barresi”, Messina, Italy, SS. Antonio e Biagio e Cesare Arrigo Hospital, Infectious Diseases Unit, Alessandria, Italy, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Infectious Diseases Unit, Department of Internal Medicine, Milan, Italy, Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio Hospital, Busto Arsizio, Italy, Infectious Disease Unit, Ospedale A. Manzoni, Lecco, Italy, Clinic of Infectious Diseases, Department of Medicine, Azienda Ospedaliera di Perugia, Santa Maria Hospital, Perugia, Italy, Unit of Infectious Diseases, University of Catania, ARNAS Garibaldi, Catania, Italy, Università degli Studi di Foggia, S.C. Malattie Infettive, Dipartimento di Medicina Clinica e Sperimentale, Foggia, Italy, University of Campania Luigi Vanvitelli, Department of Infectious Disease, Napoli, Italy, AO dei Colli, Cotugno Hospital, UOC Immunodeficiencies and Gender-Related Infectious Diseases, Napoli, Italy, University of Palermo, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Palermo, Italy, IRCCS Policlinico San Martino Hospital, Infectious Disease Clinic, Genoa, Italy General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: This study aims to compare the efficacy and safety of TAF/FTC/BIC, TAF/FTC+DTG, and TDF/FTC+DTG in HIV-naïve individuals. Method: Data from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) prospective study was analyzed. This database includes all HIV-naïve individuals initiating treatment with TAF/FTC/BIC, TAF/FTC+DTG, or TDF/FTC+DTG. We collected demographical information, risk factors for HIV infection, viro-immunological data, and causes of treatment interruption. Results: 329 HIV individuals were included; 152 (46.4%) were treated with TAF/FTC/BIC, 95 (28.6%) with TAF/FTC+DTG, and 83 (25.0%) with TDF/FTC+DTG (Figure 1). No significant difference was found in demographics and baseline virological and immunological characteristics, except for a higher percentage of PWID and a lower percentage of heterosexuals in the TDF/FTC+DTG group.At one year most patients had an HIV-RNA < 50 copies/mL; 139 (91.4%) in the TAF/FTC/BIC group, 89 (93.7%) in the TAF/FTC+DTG group, and 80 (97.6%) in TDF/FTC+DTG, without a statistically significant difference (Figure 2A). Regarding immunological response a mean difference of 266 cells/mm3 in TAF/FTC/BIC, 262 cells/mm3 in TAF/FTC+DTG, and 232 cells/mm3 in TDF/FTC+DTG, was observed vs baseline with no statistical differences. After multivariate analysis adjusting for baseline viral load, baseline CD4 cell count, age, and gender, no differences were observed between the three groups. The highest percentage of treatment interruptions was recorded in the TDF/FTC+DTG group with 12 (14.6%) versus 8 (8.4%) in the TAF/FTC+DTG group, and 14 (9.2%) in the TAF/FTC/BIC group, without a significant difference (Figure B and 2CC). After adjusting for baseline viral load, baseline CD4 cell count, age, and gender in the multivariate analysis, no differences were noted between the three groups. Concerning adverse effects, few patients reported grade 3-4 adverse events (Figure 2 D). Conclusions: Our study founf that TAF/FTC/BIC, TAF/FTC+DTG, and TDF/FTC+DTG show comparable efficacy in terms of viral suppression and immunological response, and safety in naïve people with HIV. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 2 3 4 5 6 7 8 9 10 1 11 12 13 14 15 4 16 3 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 118 19TH EUROPEAN AIDS CONFERENCE | WARSAW 2023
RkJQdWJsaXNoZXIy Mzc2ODc=